FDA lifts Clinical Hold on Selvita’s Phase I/II Clinical Trial with SEL24 in AML
Read More
Selvita researchers and academic collaborators demonstrate the potential of MNK1/2 kinase inhibitors in the treatment of c-Kit positive melanomas
Read More
Selvita Announces Full Clinical Hold on Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read More
Selvita and Menarini present together at the European Business Development Conference
Read More
Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 into Phase I for AML Patients
Read More
Institute of Hematology and Transfusion Medicine and Selvita publish joint research results in SEL24 project
Read More
Selvita presents at 18th Drug Discovery Summit in Berlin
Read More
Selvita researchers publish new paper on CDK8 inhibitor SEL120 in Oncotarget
Read More
Selvita and Menarini Group Announce Global License Agreement for Clinical Stage Oncology Drug PIM/FLT3 Inhibitor SEL24
Read More
Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
Read More
Selvita to present new data from its oncology programs at the upcoming AACR Annual Meeting 2017
Read More
Selvita researchers publish MNK inhibitors review in Current Medicinal Chemistry
Read More
